On July 5, AstraZeneca announced that it intends to acquire biotech company TeneoTwo and will receive a bispecific molecular therapy in Phase 1 clinical trials.
RED BANK, N.J., June 30, 2022 /PRNewswire/ — Provention Bio, Inc. (Nasdaq: PRVB) (the “Company”), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases,
As a new type of immunotherapy, CAR-T cell therapy boosts a patient’s killer T cells to attack and eliminate cancer. It can be as high
1. Trodelvy Trodelvy (sacituzumab govitecan-hziy) is the first approved antibody-conjugated drug targeting Trop-2 (human trophoblast cell surface antigen 2), and has been granted breakthrough therapy
1. Conjugation of Lysine ResiduesThis method attaches the payload to the lysine residue of the antibody through a linker containing an active carboxylate site. 2.
Although the research history is short and there are few types of ADC drugs on the market, these drugs play an important role in the
1. Selection of toxic small molecules: Since the small molecules of ADCs require high toxicity, affinity, and low sensitivity to multidrug resistance protein (MDR1)-mediated efflux,
On June 30, Sanofi announced that the U.S. FDA has partially suspended the Phase III study of its blockbuster drug tolebrutinib for multiple sclerosis and
On June 29, 2022, ADC Therapeutics announced that it has completed the first patient dosing of Zynlonta in the Phase 1b LOTIS-7 trial evaluating combination
The ADC linker needs to have the following 4 basic characteristics to ensure the safety and effectiveness of the ADC:(1) Maintain high stability in blood
Cancer cells are malignant tumor cells derived from epithelial cells, which have the characteristics of infinite proliferation, transformation and easy transfer. Recently, scientists have found
Structure is the key to achieving functionality. The structure of an ADC is obvious: antibody, linker, and coupled drug. Whether an ADC is successful or
